All of the following are false regarding prasugrel, except:-
**Core Concept**
Prasugrel is a thienopyridine antiplatelet agent that inhibits platelet activation and aggregation by irreversibly blocking the P2Y12 receptor on platelets. This leads to a decrease in the release of thromboxane A2, which is essential for platelet aggregation.
**Why the Correct Answer is Right**
Prasugrel is a prodrug that is metabolized to its active form, R-138727, which is responsible for its antiplatelet effects. The active metabolite of prasugrel has a higher affinity for the P2Y12 receptor compared to clopidogrel, resulting in more potent platelet inhibition. Prasugrel's mechanism of action is similar to that of clopidogrel, but it has a more rapid onset of action and a longer duration of platelet inhibition.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because prasugrel is not a prodrug of aspirin. Aspirin works by acetylating the serine residue at the active site of COX-1, leading to the inhibition of prostaglandin synthesis and subsequent reduction in thromboxane A2 production.
**Option B:** This option is incorrect because prasugrel's primary mechanism of action is not through the inhibition of the ADP receptor. While ADP does play a role in platelet activation, prasugrel's primary mechanism is through the inhibition of the P2Y12 receptor.
**Option C:** This option is incorrect because prasugrel is not primarily used for the treatment of hypertension. While prasugrel may have some effects on blood pressure, its primary use is as an antiplatelet agent in the treatment of acute coronary syndrome.
**Clinical Pearl / High-Yield Fact**
Prasugrel has a boxed warning due to its increased risk of bleeding, particularly in patients with a history of transient ischemic attack or stroke. It is essential to carefully weigh the benefits and risks of prasugrel in patients with a history of cerebrovascular events.
**Correct Answer:** C.